Gold NanoParticles / PI3k/Akt/mTOR Cancer Research Results

GoldNP, Gold NanoParticles: Click to Expand ⟱
Features:
Gold NanoParticles are often used as drug carrier. Has impressive optical properties.
Gold nanoparticles (AuNPs) are best treated as a nanomaterial “platform” (theranostic / drug-delivery / energy-enhancement adjunct) rather than a single drug. In oncology, their value comes from physics + delivery: Au strongly absorbs/scatters light (plasmonics) enabling photothermal tumor heating; it is a high-Z material that can amplify radiation dose deposition (radiosensitization); and it can be engineered (size/shape/surface ligands) to accumulate in tumors and carry payloads (drugs, immune agonists, imaging dyes). The main translation constraints are heterogeneous tumor delivery (EPR variability), biodistribution/clearance (often liver/spleen uptake), and the fact that many impressive in-vitro effects depend on exposure levels not always achieved in human tumors.

Platform : AuNP, Gold NanoParticles
Gold nanoparticles are engineered high-Z nanomaterials used in oncology primarily as (1) photothermal transducers, (2) radiosensitizers, and (3) targeted delivery/theranostic carriers. Effects are strongly dependent on particle size/shape/coating, tumor delivery (EPR/targeting), and whether an external energy source (light, radiation) is applied.

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Tumor delivery & accumulation (EPR + active targeting) Intratumoral AuNP accumulation enables all downstream modalities (PTT/RT/drug delivery); highly variable across tumors RES uptake (liver/spleen) often dominates biodistribution G Delivery constraint / enabler EPR is heterogeneous in humans; size/PEGylation/ligands alter PK, but “more targeting” does not guarantee deep tumor penetration. (EPR reality check is a major translation limiter.)
2 Photothermal conversion (plasmonic heating; NIR-triggered) Local hyperthermia → protein denaturation, membrane damage, vascular disruption → tumor cell death (when illuminated) Off-target heating risk depends on nanoparticle localization + light delivery geometry P, R Energy-to-heat tumor ablation Clinical pilot data exist for prostate focal ablation using gold nanoshell photothermal therapy (example: AuroShell-like approach). Outcome is modality-driven (light + AuNP), not “drug-like.”
3 Radiosensitization (high-Z dose enhancement) Radiation effect ↑ via increased local energy deposition + secondary electrons; can increase tumor kill if AuNPs are in/near tumor cells Normal tissue risk if AuNPs accumulate outside tumor; dose enhancement is spatially local P, R Radiotherapy amplification Most robust when tumor uptake is strong and radiation geometry overlaps AuNP distribution; mechanisms include physical dose enhancement and downstream oxidative/DNA damage amplification.
4 Drug delivery / payload carriage (chemo, siRNA, immune agonists) Higher intratumoral payload concentration; controlled release strategies can improve therapeutic index (context) Carrier uptake by RES can shift toxicity profiles (liver/spleen exposure) R, G Targeted delivery / PK shaping AuNPs are frequently used as “carriers” rather than actives. Translation hinges on reproducible manufacturing, stability, and tumor penetration beyond vasculature.
5 Theranostics (imaging + therapy) CT contrast / photoacoustic / optical tracking to confirm delivery + guide treatment Imaging may reveal off-target uptake and inform safety P, R Localization + monitoring Theranostic value is practical: confirm that nanoparticles actually reached the tumor before applying energy (light/RT) or interpreting response.
6 Tumor microenvironment (TME) remodeling & immune modulation (nanoparticle-tunable) Can alter macrophage polarization, antigen presentation, and T-cell infiltration depending on design/payload; may enhance immunotherapy (context) Systemic immune effects possible; depends on formulation and immune activation strategy G Immunomodulation (platform-dependent) Often not “gold itself,” but gold-as-carrier for immune cues; still, nanoparticle properties can influence TME and immune trafficking.
7 ROS / oxidative stress (secondary; modality-dependent) ROS ↑ can occur after PTT/RT amplification or via surface/catalytic effects; may contribute to apoptosis/necrosis Oxidative stress is a general tissue-injury mechanism if exposure is off-target or excessive P, R Stress amplification ROS is usually a downstream mediator of (a) radiation enhancement or (b) thermal injury/inflammation. It is rarely the primary “intent” unless AuNPs are coupled to photodynamic/ROS-generating systems.
8 Nrf2 / antioxidant response (resistance / protection axis) Nrf2 activation in tumors can blunt ROS-mediated killing (radio/thermal/chemo stress), potentially reducing efficacy in high-Nrf2 tumors Nrf2 is generally protective in normal tissues against oxidative injury G Response modifier Nrf2 is not a primary AuNP mechanism but can explain variable sensitivity: if the therapeutic effect is ROS/stress-mediated, Nrf2-high tumors may be more resistant; in normal tissue Nrf2 is usually a safety buffer.
9 Clearance / persistence (RES uptake; long-term burden) Limits effective tumor dosing if most particles are sequestered; chronic retention is a concern depending on size/coating Liver/spleen accumulation is common; long-term safety depends on formulation and dose G Translation constraint Unlike small molecules, “elimination” can be slow; engineering (size, shape, coating) trades off circulation time vs clearance vs tumor uptake.
10 Clinical evidence status (heterogeneous; indication-specific) Human data exist for specific AuNP modalities (e.g., photothermal nanoshell approaches), but broad claims should be avoided — — Reality check AuNPs are best framed as adjuncts to established modalities (light/RT/drug delivery). Most “pan-cancer” statements fail because delivery, tumor geometry, and modality coupling dominate outcomes.

Time-Scale Flag (TSF): P = 0–30 min (energy deposition / immediate physicochemical effects), R = 30 min–3 hr (acute stress signaling, early injury response), G = >3 hr (immune remodeling, clearance, adaptation/phenotypes).
PI3k/Akt/mTOR, Phosphoinositide 3-kinase/Protein Kinase B/ mammalian target of rapamycin: Click to Expand ⟱
Source:
Type:
The PI3K/Akt/mTOR signaling pathway is a critical regulator of cell growth, proliferation, survival, and metabolism.

In many cancers (such as breast, colorectal, lung, and endometrial cancers), the PI3K/Akt/mTOR pathway is often hyperactivated.

– This hyperactivation is frequently due to gene mutations (e.g., in PIK3CA), loss of PTEN, and amplification events that enhance the pathway’s activity.

– Increased activity is also observed via elevated levels of phosphorylated Akt and mTOR in tumors compared to normal tissues.
Scientific Papers found: Click to Expand⟱
62- QC,  GoldNP,    Gold nanoparticles-conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt-mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB-231)
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
EGFR↓, PI3k/Akt/mTOR↓, GSK‐3β↓, TumCP↓, Apoptosis↑, tumCV↓, mTOR↓, PTEN↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

PI3k/Akt/mTOR↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,   mTOR↓, 1,   PTEN↑, 1,  

Migration ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PI3k/Akt/mTOR, Phosphoinositide 3-kinase/Protein Kinase B/ mammalian target of rapamycin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:180  Target#:254  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page